stroke
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Aged 30-75 years old; (2) It meets the diagnostic criteria of "Stroke" formulated by the Fourth National Cerebrovascular Disease Academic Conference and is clearly diagnosed by CT or MRI, the course of the disease is more than 2 weeks, and the vital signs are stable within 6 months; (3) Unilateral lesions, which are located in the nucleus basalis area of the inner capsule, involving white matter but no gray matter; (4) The wrist of the affected side can actively extend back at least 10°, and the other two fingers except the thumb can extend back at least 10 degree; (5) The modified Ashworth classification of the affected upper limb <=1+; (6) Able to walk independently and have sufficient balance; (7) No cognitive impairment, able to cooperate with treatment and evaluation; (8) Willing to obey guidance and have a good desire for recovery and good family support; (9) Patient and his/her family members willing to sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients who have previously suffered from Parkinson's disease, peripheral neuropathy and other motor dysfunctions; (2) Those who have severe cognitive, speech, vision, hearing, or mental disorders that affect inspection and treatment; (3) Patients who have not had a stroke for the first time or who have had a lacunar infarction in the past and have sequelae; (4) Patients with tumors, severe respiratory, heart, liver, kidney, endocrine and hematopoietic diseases; (5) Those who have a history of epilepsy or a family history of epilepsy, have a metal pacemaker in their body, have metal implants in the brain, cochlear implants, etc. who are not suitable for transcranial magnetic stimulation treatment; (6) Those who have a history of alcohol or drug abuse; (7) Pregnant and lactating women; (8) Those who are participating in other clinical trials that affect the evaluation of the results of this study; (9) Those who cannot complete the basic course of treatment, who may have poor compliance (that is, who cannot adhere to treatment) and who are difficult to follow up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ARAT;WMFT; | — |
Secondary
| Measure | Time frame |
|---|---|
| FMA;FIM;MT;CMCT; | — |
Countries
China
Contacts
Huashan Hospital North, Fudan University